Efficacy and Safety of Semaglutide Once-weekly Versus Exenatide ER 2.0 mg Once-weekly as add-on to 1-2 Oral Antidiabetic Drugs (OADs) in Subjects With Type 2 Diabetes

clinical trial

Efficacy and Safety of Semaglutide Once-weekly Versus Exenatide ER 2.0 mg Once-weekly as add-on to 1-2 Oral Antidiabetic Drugs (OADs) in Subjects With Type 2 Diabetes is …
instance of (P31):
clinical trialQ30612

External links are
P3098ClinicalTrials.gov IDNCT01885208

P6099clinical trial phasephase III clinical trialQ42824827
P17countryUnited States of AmericaQ30
FinlandQ33
SwitzerlandQ39
NetherlandsQ55
ItalyQ38
United KingdomQ145
SerbiaQ403
GreeceQ41
FranceQ142
ArgentinaQ414
GermanyQ183
CroatiaQ224
P582end time2015-07-13
P131located in the administrative territorial entityPuerto RicoQ1183
P1050medical conditiondiabetesQ12206
P2899minimum age18
P1132number of participants813
P4844research interventionexenatideQ417762
P6153research siteNovo NordiskQ818846
P1813short nameSUSTAIN™ 3
P580start time2013-12-02
P8363study typeinterventional studyQ78089383
P1476titleEfficacy and Safety of Semaglutide Once-weekly Versus Exenatide ER 2.0 mg Once-weekly as add-on to 1-2 Oral Antidiabetic Drugs (OADs) in Subjects With Type 2 Diabetes (SUSTAIN™ 3 - vs. QW GLP-1)

Search more.